Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma.

Saletta, F; Vilain, RE; Gupta, AK; Nagabushan, S; Yuksel, A; Catchpoole, D; Scolyer, RA; Byrne, JA; McCowage, G

Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma.

Saletta, F Vilain, RE Gupta, AK Nagabushan, S Yuksel, A Catchpoole, D

Scolyer, RA Byrne, JA McCowage, G

Permalink

Publisher:: American Society of Clinical Oncology
Publication Type:: Journal Article
Citation:: JCO Precision Oncology, 2017, 1, (1), pp. 1-12
Issue Date:: 2017-11

Closed Access

	Filename	Description	Size
	po.16.00049.pdf		1.34 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Saletta, F
dc.contributor.author	Vilain, RE
dc.contributor.author	Gupta, AK
dc.contributor.author	Nagabushan, S
dc.contributor.author	Yuksel, A
dc.contributor.author	Catchpoole, D https://orcid.org/0000-0001-5836-1413
dc.contributor.author	Scolyer, RA
dc.contributor.author	Byrne, JA
dc.contributor.author	McCowage, G
dc.date.accessioned	2022-09-09T02:35:22Z
dc.date.available	2022-09-09T02:35:22Z
dc.date.issued	2017-11
dc.identifier.citation	JCO Precision Oncology, 2017, 1, (1), pp. 1-12
dc.identifier.issn	2473-4284
dc.identifier.issn	2473-4284
dc.identifier.uri	http://hdl.handle.net/10453/161570
dc.description.abstract	PURPOSE: Programmed death-ligand 1 (PD-L1) expression represents a potential predictive biomarker of immune checkpoint blockade response. However, literature about the prevalence of PD-L1 expression in the pediatric cancer setting is discordant. METHODS: PD-L1 expression was analyzed using immunohistochemistry in 500 pediatric tumors (including neuroblastoma, sarcomas, and brain cancers). Tumors with ≥ 1% cells showing PD-L1 membrane staining of any intensity were scored as positive. Positive cases were further characterized, with cases with weak intensity PD-L1 staining reported as having low PD-L1 expression and cases with a moderate or strong intensity of staining considered to have high PD-L1 expression. RESULTS: PD-L1-positive staining was identified in 13% of cases, whereas high PD-L1 expression was found in 3% of cases. Neuroblastoma (n = 254) showed PD-L1 expression of any intensity in 18.9% of cases and was associated with longer overall survival (P = .045). However, high PD-L1 expression in neuroblastoma (3.1%) was significantly associated with an increased risk of relapse (P = .002). Positive PD-L1 staining was observed more frequently in low- and intermediate-risk patients (P = .037) and in cases lacking MYCN amplification (P = .002). CONCLUSION: In summary, high PD-L1 expression in patients with neuroblastoma may represent an unfavorable prognostic factor associated with a higher risk of cancer relapse. This work proposes PD-L1 immunohistochemical assessment as a novel parameter for identifying patients with an increased likelihood of cancer recurrence.
dc.format	Print
dc.language	eng
dc.publisher	American Society of Clinical Oncology
dc.relation.ispartof	JCO Precision Oncology
dc.relation.isbasedon	10.1200/PO.16.00049
dc.rights	info:eu-repo/semantics/closedAccess
dc.title	Programmed Death-Ligand 1 Expression in a Large Cohort of Pediatric Patients With Solid Tumor and Association With Clinicopathologic Features in Neuroblastoma.
dc.type	Journal Article
utslib.citation.volume	1
utslib.location.activity	United States
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2022-09-09T02:35:20Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	1
utslib.citation.issue	1

Abstract:

PURPOSE: Programmed death-ligand 1 (PD-L1) expression represents a potential predictive biomarker of immune checkpoint blockade response. However, literature about the prevalence of PD-L1 expression in the pediatric cancer setting is discordant. METHODS: PD-L1 expression was analyzed using immunohistochemistry in 500 pediatric tumors (including neuroblastoma, sarcomas, and brain cancers). Tumors with ≥ 1% cells showing PD-L1 membrane staining of any intensity were scored as positive. Positive cases were further characterized, with cases with weak intensity PD-L1 staining reported as having low PD-L1 expression and cases with a moderate or strong intensity of staining considered to have high PD-L1 expression. RESULTS: PD-L1-positive staining was identified in 13% of cases, whereas high PD-L1 expression was found in 3% of cases. Neuroblastoma (n = 254) showed PD-L1 expression of any intensity in 18.9% of cases and was associated with longer overall survival (P = .045). However, high PD-L1 expression in neuroblastoma (3.1%) was significantly associated with an increased risk of relapse (P = .002). Positive PD-L1 staining was observed more frequently in low- and intermediate-risk patients (P = .037) and in cases lacking MYCN amplification (P = .002). CONCLUSION: In summary, high PD-L1 expression in patients with neuroblastoma may represent an unfavorable prognostic factor associated with a higher risk of cancer relapse. This work proposes PD-L1 immunohistochemical assessment as a novel parameter for identifying patients with an increased likelihood of cancer recurrence.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/161570